113 results on '"Siddiqui, Mustaqeem A."'
Search Results
2. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States
3. Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients
4. Immunotherapy in multiple myeloma
5. Evidence-Based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region.
6. Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)
7. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities
8. Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy
9. A simple additive staging system for newly diagnosed multiple myeloma
10. Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia
11. Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy
12. Correction: MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients
13. Management of secondary immunodeficiency in hematological malignancies: a Delphi consensus from the Middle East.
14. MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients
15. Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients
16. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response
17. Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset
18. Prognostic impact of combined NPM1+/FLT3− genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities
19. Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
20. Risk Factors for Readmission in Patients With Cancer Comanaged by Hospitalists
21. The High Cost of Cancer Drugs and What We Can Do About It
22. Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma
23. Implementing SAFER Responses to Misconduct and Responding to Biased Patient Requests ASAP.
24. 47 - Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
25. In reply
26. Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients.
27. Prognostic significance of acquired 1q22 gain in multiple myeloma.
28. Absolute lymphocyte count predicts overall survival in follicular lymphomas
29. 21-Year-Old Woman With Flank Pain
30. P-209: Deepening responses post upfront ASCT in newly diagnosed multiple myeloma in the era of novel agent induction therapy
31. P-164: Daratumumab, carfilzomib, pomalidomide and elotuzumab for the treatment of poems syndrome: the Mayo Clinic experience
32. Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide.
33. A Taxonomic Review of Patient Complaints in Adult Hospital Medicine.
34. Colon perforation in multiple myeloma patients – A complication of high‐dose steroid treatment.
35. Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio.
36. 230 - Outpatient Practice Pattern and Clinical Outcome for Axicabtagene Ciloleucel in Patients with Aggressive Lymphoma
37. The Use of Empathic Communication During the COVID-19 Outbreak.
38. Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis
39. Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients
40. Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM)
41. Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)
42. Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM)
43. The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma
44. MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients
45. A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders
46. Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma
47. Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis
48. Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma
49. Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition
50. Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.